Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
McKesson
Colorcon
McKinsey
Moodys

Last Updated: May 28, 2022

CLINICAL TRIALS PROFILE FOR THIAMINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Thiamine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00031057 ↗ Vitamin B Therapy for Hyperlactatemia Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 1969-12-31 The purpose of this study is to see if vitamin B can treat mild hyperlactatemia (a higher than normal level of lactate in the blood) in patients who take nucleoside reverse transcriptase inhibitors (NRTIs). Hyperlactatemia is a potentially life-threatening condition that can be associated with NRTI therapy. A lack of vitamin B may be related to the development of hyperlactatemia. However, no studies have been done to evaluate this. This study proposes that high doses of vitamin B may bring elevated lactate levels back to normal among patients taking NRTIs.
NCT00143702 ↗ D4T or Abacavir Plus Vitamin Enhancement in HIV-Infected Patients (DAVE) Completed CIHR Canadian HIV Trials Network Phase 2/Phase 3 2001-08-01 The purpose of this study is to determine the best way to treat people on d4T (stavudine) with high levels of lactic acid. Switching from d4T to abacavir will be assessed. Adding riboflavin and thiamine will also be assessed. Participants will be randomly assigned to one of four groups: - Group 1 participants will continue to take d4T as part of their antiretroviral (ARV) regimen, and will be given the vitamin supplements - Group 2 will continue to take d4T without vitamin supplements - Group 3 will switch from d4T to abacavir and receive the vitamins - Group 4 will switch from d4T to abacavir without vitamin supplements. The study plans to involve eighty participants from Canada and Argentina for a treatment period of 16 weeks and a follow-up visit at week 24.
NCT00143702 ↗ D4T or Abacavir Plus Vitamin Enhancement in HIV-Infected Patients (DAVE) Completed GlaxoSmithKline Phase 2/Phase 3 2001-08-01 The purpose of this study is to determine the best way to treat people on d4T (stavudine) with high levels of lactic acid. Switching from d4T to abacavir will be assessed. Adding riboflavin and thiamine will also be assessed. Participants will be randomly assigned to one of four groups: - Group 1 participants will continue to take d4T as part of their antiretroviral (ARV) regimen, and will be given the vitamin supplements - Group 2 will continue to take d4T without vitamin supplements - Group 3 will switch from d4T to abacavir and receive the vitamins - Group 4 will switch from d4T to abacavir without vitamin supplements. The study plans to involve eighty participants from Canada and Argentina for a treatment period of 16 weeks and a follow-up visit at week 24.
NCT00143702 ↗ D4T or Abacavir Plus Vitamin Enhancement in HIV-Infected Patients (DAVE) Completed University of British Columbia Phase 2/Phase 3 2001-08-01 The purpose of this study is to determine the best way to treat people on d4T (stavudine) with high levels of lactic acid. Switching from d4T to abacavir will be assessed. Adding riboflavin and thiamine will also be assessed. Participants will be randomly assigned to one of four groups: - Group 1 participants will continue to take d4T as part of their antiretroviral (ARV) regimen, and will be given the vitamin supplements - Group 2 will continue to take d4T without vitamin supplements - Group 3 will switch from d4T to abacavir and receive the vitamins - Group 4 will switch from d4T to abacavir without vitamin supplements. The study plans to involve eighty participants from Canada and Argentina for a treatment period of 16 weeks and a follow-up visit at week 24.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Thiamine Hydrochloride

Condition Name

Condition Name for Thiamine Hydrochloride
Intervention Trials
Septic Shock 17
Sepsis 17
Thiamine Deficiency 7
Lactic Acidosis 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Thiamine Hydrochloride
Intervention Trials
Shock, Septic 21
Sepsis 16
Shock 14
Toxemia 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Thiamine Hydrochloride

Trials by Country

Trials by Country for Thiamine Hydrochloride
Location Trials
United States 59
Brazil 8
Canada 4
China 3
Egypt 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Thiamine Hydrochloride
Location Trials
Massachusetts 12
New York 6
Arizona 3
California 3
Ohio 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Thiamine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Thiamine Hydrochloride
Clinical Trial Phase Trials
Phase 4 17
Phase 3 14
Phase 2/Phase 3 5
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Thiamine Hydrochloride
Clinical Trial Phase Trials
Completed 42
Recruiting 16
Unknown status 9
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Thiamine Hydrochloride

Sponsor Name

Sponsor Name for Thiamine Hydrochloride
Sponsor Trials
Beth Israel Deaconess Medical Center 9
University of Aarhus 2
University Medical Centre Ljubljana 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Thiamine Hydrochloride
Sponsor Trials
Other 143
NIH 8
U.S. Fed 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Dow
Moodys
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.